Journal · Pain medicine · Updated 21 November 2026
Current Pain and Headache Reports
Read Current Pain and Headache Reports articles on DeepDyve. No university library needed.
Current Pain and Headache Reports publishes reviews across pain medicine and headache disorders, from migraine prevention to pain management around surgery. Springer Nature publishes it. It was previously published as Current Review of Pain. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Current Pain and Headache Reports at a glance
- Full title
- Current Pain and Headache Reports
- Former title
- Current Review of Pain
- Abbreviation (NLM)
- Curr Pain Headache Rep
- Publisher
- Springer Nature
- Print ISSN
- 1531-3433
- Online ISSN (eISSN)
- 1534-3081
- Current title since
- 2001
- Subjects
- Neurology, Psychophysiology
- Access model
- Hybrid (27% free to read in 2026)
Ways to access Current Pain and Headache Reports
27% of the articles Current Pain and Headache Reports published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 27% of Current Pain and Headache Reports articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Current Pain and Headache Reports. Check its journal list and whether it offers remote access.
- DeepDyve. Read Current Pain and Headache Reports articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Current Pain and Headache Reports’ 2025 Journal Impact Factor is 4.8, and its 5-year Impact Factor is 4.5.
4.8
Journal Impact Factor (2025)
4.5
5-year Impact Factor (2025)
15 days
Median time to first decision
Source: journal metrics on the Current Pain and Headache Reports homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Current Pain and Headache Reports research worth reading
Published January to May 2026. Summaries describe what the authors report.
-
Selective NaV1.8 Inhibition for Pain Management: Current Evidence and Future Potential of Suzetrigine
Abd-Elsayed and colleagues review suzetrigine, approved by the FDA in 2025 as the first highly selective oral NaV1.8 inhibitor, noting that phase 3 trials indicate analgesia for moderate to severe acute postoperative pain comparable to opioid therapy without respiratory depression, sedation or dependence.
Abd-Elsayed et al. · Current Pain and Headache Reports, published online March 17, 2026 · DOI 10.1007/s11916-026-01472-w
-
Efficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Pooling nine randomised controlled trials (n = 788), the authors report that melatonin reduced migraine attack duration, headache days, severity and analgesic use versus placebo, and was generally less effective than amitriptyline for attack duration and severity but better tolerated.
Abouelmagd et al. · Current Pain and Headache Reports, published online February 2, 2026 · DOI 10.1007/s11916-025-01461-5
-
The Interictal State of Migraine: Understanding the Hidden Burden Between Attacks
Patel and colleagues review the interictal state of migraine, the time between attacks, noting that several large studies using tools such as the Migraine Interictal Burden Scale have documented severe interictal burden in a majority of patients.
Patel et al. · Current Pain and Headache Reports, published online January 6, 2026 · DOI 10.1007/s11916-025-01459-z
-
The Management of Myogenous Temporomandibular Disorders with Botulinum Toxin: A Narrative Review and Management Recommendations
In a narrative review, Mathew and colleagues conclude that botulinum toxin can be effective for myogenous temporomandibular disorders that have not responded to conventional therapy, but that it is not a first-line treatment and there are no standardized injection protocols.
Mathew et al. · Current Pain and Headache Reports, published online February 4, 2026 · DOI 10.1007/s11916-025-01463-3
-
Applications of Celiac Plexus Block in Chronic Pancreatitis or Pancreatic Cancer
Ke and colleagues review celiac plexus block for upper abdominal pain, concluding that current evidence suggests it is highly effective for pancreatic cancer pain but gives only modest, short-lived benefit in chronic pancreatitis, where it should be reserved for carefully selected refractory cases.
Ke et al. · Current Pain and Headache Reports, published online May 7, 2026 · DOI 10.1007/s11916-026-01495-3
See every Current Pain and Headache Reports article on DeepDyve
Related journals
Questions about Current Pain and Headache Reports
How can I read Current Pain and Headache Reports articles without a subscription?
27% of Current Pain and Headache Reports articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Pain and Headache Reports articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Current Pain and Headache Reports?
Current Pain and Headache Reports’ NLM (PubMed) abbreviation is Curr Pain Headache Rep.
What is the ISSN of Current Pain and Headache Reports?
The print ISSN is 1531-3433 and the online ISSN is 1534-3081.
What is the impact factor of Current Pain and Headache Reports?
Current Pain and Headache Reports’ Journal Impact Factor is 4.8 (2025), and its 5-year Impact Factor is 4.5, according to Springer Nature’s published metrics.
Is Current Pain and Headache Reports open access?
Current Pain and Headache Reports is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 33 of 123 Current Pain and Headache Reports articles (27%) carry a Creative Commons license, per Crossref.
Current Pain and Headache Reports articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.
Start reading Current Pain and Headache Reports today
One month free, then less than $2 a day. Current Pain and Headache Reports, plus millions of articles from thousands of journals.





